How cancer immunotherapy works
How cancer immunotherapy works Cancer immunotherapy represents a groundbreaking approach in the fight against cancer, harnessing the body’s own immune system to recognize and destroy malignant cells. Unlike traditional treatments such as chemotherapy and radiation, which directly target cancer cells but often come with significant side effects, immunotherapy aims to boost or restore the immune system’s natural ability to fight cancer more selectively and effectively.
The immune system is inherently equipped to identify and eliminate abnormal cells, including potential cancer cells. However, cancer has evolved sophisticated mechanisms to evade immune detection. It can produce signals that suppress immune responses or hide from immune cells altogether. Immunotherapy works by disrupting these cancer strategies and empowering the immune system to mount a stronger attack. How cancer immunotherapy works
One of the most widely recognized forms of immunotherapy involves immune checkpoint inhibitors. These are drugs designed to block specific proteins on immune cells or cancer cells that act as “brakes” on immune responses. For example, proteins such as PD-1, PD-L1, and CTLA-4 normally help prevent immune cells from attacking healthy tissues, but cancers can exploit these checkpoints to avoid immune destruction. Checkpoint inhibitors, like pembrolizumab and nivolumab, release these brakes, allowing immune cells, particularly T-cells, to recognize and attack cancer cells more effectively.
Another approach is the use of monoclonal antibodies, which are lab-made molecules that can specifically target antigens on cancer cells. Some of these antibodies can mark cancer cells for destruction by immune cells through a process called antibody-dependent cellular cytotoxicity, while others can deliver toxic payloads directly to cancer cells. Additionally, certain monoclonal antibodies are designed to block growth signals that tumors rely on, inhibiting their progression.
Cancer vaccines are also a form of immunotherapy, aiming to stimulate the immune system to recognize specific tumor-associated antigens. These vaccines can be preventive, such as the HPV vaccine to prevent cervical cancer, or therapeutic, designed to stimulate an immune response against existing tumors. How cancer immunotherapy works
How cancer immunotherapy works Adoptive cell transfer is a more personalized form of immunotherapy. It involves collecting a patient’s immune cells, usually T-cells, expanding or modifying them in the laboratory to better target cancer cells, and then reinfusing them into the patient. Chimeric antigen receptor (CAR) T-cell therapy is a prominent example, where T-cells are engineered to express receptors that can specifically recognize cancer antigens, leading to a potent immune attack.
How cancer immunotherapy works While immunotherapy has shown remarkable success in treating certain cancers, such as melanoma, lung cancer, and some blood cancers, it is not universally effective. Researchers continue to explore combination therapies, biomarkers for predicting responses, and new agents to expand the benefits of immunotherapy to more patients.
How cancer immunotherapy works In summary, cancer immunotherapy works by modifying or enhancing the immune system’s natural ability to detect and destroy cancer cells. By targeting specific pathways and mechanisms cancer uses to evade immune responses, these therapies offer hope for more effective and less toxic treatments, transforming the landscape of oncology.
